Keyword: Bristol-Myers Squibb
Bristol-Myers Squibb will move about 90 manufacturing jobs from its DeWitt, New York, facility to plants in Massachusetts and New Jersey.
Officials in Japan have moved to swiftly cut the price on two top-selling cancer meds.
BMS has longevity and strong data on its side when it comes to staying on top of the immuno-oncology field. But a convenience boost can’t hurt.
Emotion is a strong decision driver, especially in healthcare—so important, in fact, that Havas Health & You has launched a new agency to focus on it.
Some drugmakers reap far more savings from tax reform than others—and some will actually have to pay more. Here's our report card.
The math is simple, but managing a company isn’t. That’s the message we gleaned in analyzing productivity at major pharmas and biotech companies.
The same day that Bristol-Myers Squibb reported a closely watched clinical win, the drugmaker announced Street-beating results.
Bristol-Myers finally got its win in first-line lung cancer, with a one-two punch of its PD-1 drug Opdivo and CTLA4 drug Yervoy.
Two European manufacturing plants discarded by Big Pharma have been bought by Asian companies and reopened.